Related Experiment Video
Updated: Jun 30, 2026
07:25
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Resistance issues in treating chronic hepatitis B.
George V Papatheodoridis1, Melanie Deutsch
1Athens University Medical School, 2nd Department of Internal Medicine, Hippokration General Hospital of Athens, Athens, Greece. gepapath@med.uoa.gr
Future Microbiology
|September 25, 2008
Summary
Hepatitis B virus (HBV) resistance limits oral polymerase inhibitor therapy. Close monitoring and combination therapy are crucial for managing chronic HBV infection and preventing resistance.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Hepatitis B virus (HBV) polymerase inhibitors are standard for chronic hepatitis B.
- Viral resistance is a major challenge for long-term treatment efficacy.
- Complete suppression of HBV replication is key to minimizing resistance development.
Purpose of the Study:
- To review the resistance profiles of common oral anti-HBV agents.
- To provide guidance on optimal treatment strategies for chronic hepatitis B.
- To highlight the importance of monitoring and combination therapy.
Main Methods:
- Literature review of HBV polymerase inhibitors.
- Analysis of resistance mutation profiles for various antiviral agents.
- Comparison of treatment efficacy and resistance rates.
Main Results:
- Lamivudine monotherapy exhibits the highest risk of resistance.
- Adefovir is less potent than tenofovir.
- Telbivudine resistance profiles are unclear and may select for lamivudine resistance.
- Entecavir and tenofovir show the best resistance profiles in nucleoside-naive patients.
- Tenofovir is optimal for patients with lamivudine resistance.
Conclusions:
- Close monitoring of HBV DNA levels (every 6 months) is essential.
- Combination therapy with agents lacking cross-resistance is recommended for patients with HBV resistance.
- Entecavir and tenofovir are preferred agents due to potency and resistance profiles.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:17Chronic Bowel Disorders: Introduction
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:23Cirrhosis I: Introduction
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...